Faron reports 43% complete remission rate in MDS
Faron Pharmaceuticals has announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase I/II BEXMAB trial.
According to the investigator-assessed response using IWG 2006 criteria, as per protocol, the CR rate has increased to 43% (nine out of 21 patients), a substantial improvement from the 28% rate seen in the earlier data cut.
The company says the improvement in CR is a result of patient responses improving as they continue longer on the combination therapy of bexmarilimab and the standard-of-care, azacitidine.
The updated efficacy data was prepared for an upcoming End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (FDA).
CR signifies a return to normal blood cell counts and bone marrow cellularity. The 43% CR rate achieved with the bexmarilimab combination is more than double the 16-17% historical rate seen in patients treated with azacitidine alone.
Earlier data from the BEXMAB study had also reported a 50% composite CR rate (cCR) in frontline HR-MDS patients.
“The continued maturation of the BEXMAB data demonstrates bexmarilimab’s profound impact as a disease-modifying agent,” said Dr Petri Bono, Chief Medical Officer of Faron. “Seeing the CR rate strengthen over time to 43%, which complements the robust 50% cCR we have already reported, is very encouraging. It provides us with two compelling and clinically meaningful data sets for discussion with the FDA and gives us confidence in proposing a randomised registrational trial designed for accelerated approval with either CR or cCR as the primary endpoint.”
According to Faron, by targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumour microenvironment, reprogramming macrophages to an immunostimulatory state, upregulating interferon production and priming the immune system to attack tumours and sensitising cancer cells to standard of care.
Diana Turner, Senior Digital Content Editor, DDW
